ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,22
-1,51%
Dow Jones
42 732,13
0,80%
DAX
19 906,08
-0,49%
Brent Oil
76,495
0,00%
Bitcoin
98 046,49
-0,06%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cullinan Therapeutics Inc (CGEM)

  7. Cullinan Therapeutics Inc (CGEM) Actualités

CGEM

Cullinan Therapeutics (CGEM)

Cullinan Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CGEM
DateHeureSourceTitreSymboleSociété
20/12/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
14/11/202423h05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CGEMCullinan Therapeutics Inc
14/11/202416h01GlobeNewswire Inc.Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024NASDAQ:CGEMCullinan Therapeutics Inc
08/11/202420h17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CGEMCullinan Therapeutics Inc
07/11/202413h18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGEMCullinan Therapeutics Inc
07/11/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
07/11/202413h00GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
05/11/202413h00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare ConferenceNASDAQ:CGEMCullinan Therapeutics Inc
04/11/202413h00GlobeNewswire Inc.Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/10/202413h00GlobeNewswire Inc.Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
17/09/202413h00GlobeNewswire Inc.Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
16/09/202413h00GlobeNewswire Inc.Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
14/09/202410h15GlobeNewswire Inc.Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024NASDAQ:CGEMCullinan Therapeutics Inc
05/09/202422h27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
28/08/202414h00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CGEMCullinan Therapeutics Inc
08/08/202413h00GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
05/06/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGEMCullinan Therapeutics Inc
04/06/202423h06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CGEMCullinan Therapeutics Inc
01/06/202413h00GlobeNewswire Inc.Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of ZipalertinibNASDAQ:CGEMCullinan Therapeutics Inc
24/05/202414h00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:CGEMCullinan Therapeutics Inc
23/05/202423h04GlobeNewswire Inc.Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/05/202422h10Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CGEMCullinan Therapeutics Inc
16/05/202413h30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CGEMCullinan Therapeutics Inc
16/05/202412h42Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CGEMCullinan Therapeutics Inc
16/05/202412h40Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CGEMCullinan Therapeutics Inc
15/05/202422h05GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
29/04/202413h00GlobeNewswire Inc.Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerNASDAQ:CGEMCullinan Therapeutics Inc
24/04/202416h09GlobeNewswire Inc.Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/04/202413h00GlobeNewswire Inc.Cullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesNASDAQ:CGEMCullinan Therapeutics Inc
16/04/202412h59GlobeNewswire Inc.Cullinan Therapeutics Announces Oversubscribed $280 million Private PlacementNASDAQ:CGEMCullinan Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CGEM

Dernières Valeurs Consultées

EU
DG
Vinci
COIN
BTCUSD
Bitcoin
NASDAQ
GOOGL
Alphabet
NYSE
JPM
JP Morgan Chase
EU
ACA
Credit Agricole
NASDAQ
NVDA
NVIDIA
EU
RI
Pernod Ricard
NASDAQ
MSFT
Microsoft
USI
USTECH100
US Tech 100
EU
VK
Vallourec
EU
EN
Bouygues
NASDAQ
AMZN
Amazon.com
EU
BN
Danone
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés